Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chantana Polprasert

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Oncotarget|December 30, 2016
Recurrent genetic defects on chromosome 5q in myeloid neoplasmsNaoko Hosono, Hideki Makishima, Reda Mahfouz, et al.
The Lancet. Oncology|December 10, 2020
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 studyJacob P Laubach, Fredrik Schjesvold, Mário Mariz, et al.
Haematologica|May 24, 2015
BRCC3 mutations in myeloid neoplasmsDayong Huang, Yasunobu Nagata, Vera Grossmann, et al.
Cancer Cell|April 30, 2015
Inherited and Somatic Defects in DDX41 in Myeloid NeoplasmsChantana Polprasert, Isabell Schulze, Mikkael A Sekeres, et al.
Blood|November 2, 2022
Germ line DDX41 mutations define a unique subtype of myeloid neoplasmsHideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, et al.
Nature Medicine|August 5, 2020
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Yasuhito Nannya, Robert P Hasserjian, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Oncotarget|December 30, 2016
Recurrent genetic defects on chromosome 5q in myeloid neoplasmsNaoko Hosono, Hideki Makishima, Reda Mahfouz, et al.
The Lancet. Oncology|December 10, 2020
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 studyJacob P Laubach, Fredrik Schjesvold, Mário Mariz, et al.
Haematologica|May 24, 2015
BRCC3 mutations in myeloid neoplasmsDayong Huang, Yasunobu Nagata, Vera Grossmann, et al.
Cancer Cell|April 30, 2015
Inherited and Somatic Defects in DDX41 in Myeloid NeoplasmsChantana Polprasert, Isabell Schulze, Mikkael A Sekeres, et al.
Blood|November 2, 2022
Germ line DDX41 mutations define a unique subtype of myeloid neoplasmsHideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, et al.
Nature Medicine|August 5, 2020
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Yasuhito Nannya, Robert P Hasserjian, et al.
Pageof 5